BIOBANK acquired by IK PARTNERS

Advanced Instruments has finalized the acquisition of Nova Biomedical, a maneuver designed to fundamentally reshape the global biopharma analytics and clinical diagnostic landscape. The strategic rationale for this transaction centers on a "portfolio-convergence" play, merging the target's industry-leading point-of-care and bioprocess monitoring technology with the group’s established leadership in osmometry and specialized lab analytics. This fusion effectively creates a specialized powerhouse in the life sciences tools sector, providing the organization with an end-to-end suite of analytical hardware required for modern drug development and patient monitoring.

BC Partners, a leading European investment firm, and Bpifrance have finalized the landmark acquisition of Biogaran from Servier. As a cornerstone of the French pharmaceutical industry and the domestic leader in generic medicines, Biogaran enters a new phase of independence. The transaction was completed on January 30, 2026, following regulatory approvals and strict oversight regarding foreign investment in France.

Private equity firm Mérieux Equity Partners has entered into a definitive agreement to divest its controlling equity stake in the pharmaceutical laboratory Theravia to the Dutch group Norgine, a portfolio company backed by Goldman Sachs Asset Management. Representing the sixth exit for the Mérieux Equity Participations 3 fund, this transaction facilitates the complete exit of the sponsor, which had held a near-80% ownership position since Theravia's inception through a corporate merger in 2022. The completion of the deal remains subject to the receipt of customary regulatory approvals. For the acquirer Norgine, led by CEO Janneke van der Kamp, this integration is a core component of its expansion strategy, designed to solidify its standing as a partner of choice for the commercialization of specialty pharmaceuticals across Europe. Theravia’s innovative treatments, such as Orphacol and Siklos, perfectly complement Norgine’s existing pipeline—which already features therapies like Pedmarqsi and Mavorixafor. This highly synergistic combination expands the group's core rare disease franchise to a total of six strategic products. For Theravia and its CEO Franck Hamalian, partnering with an established industrial player boasting substantial European commercial firepower provides a critical opportunity to accelerate patient access to life-saving medications for severe unmet medical needs, driven by a shared strategic vision for continuous innovation in the rare disease sector.

Sterimed completes its third buy-out (LBO) as IK Partners returns as the majority shareholder, taking over from Sagard. This transaction values the group at over EUR1 billion, a significant jump from its previous valuation. Under Sagard's ownership, Sterimed accelerated its international expansion, notably in North America and Asia. The new partnership with IK Partners aims to further consolidate the medical packaging market through a global buy-and-build strategy and to invest in sustainable, eco-friendly sterilization solutions.

Patient Square Capital completed the acquisition of 100% of Patterson Companies, taking the business private and delisting it from the NASDAQ Global Select Market. Patterson will maintain its headquarters in St. Paul, Minnesota. The transaction positions Patterson to accelerate its growth strategy and strengthen its offering to dental and animal health customers under Patient Square's healthcare-focused ownership and operational support.

Ceva organized its sixth LBO to support its continued growth. The transaction values the group at over EUR9 billion (nearly double the EUR5bn valuation in 2020). Two new shareholders joined the table: Institut Merieux (strengthening the existing presence of Merieux Equity Partners) and Archimed (investing via its large-cap fund). Historical investors, including Tethys and PSP, significantly reinvested. Crucially, the management team led retains control of the voting rights (60%) despite holding 23% of the capital.

Cinven acquires a majority stake in the French clinical nutrition group Nutrisens from Sagard. The transaction values the company at over EUR700 million. Under Sagard's tenure, Nutrisens tripled its size through organic growth and acquisitions. With Cinven's backing, the group aims to become a global platform in the fragmented medical nutrition market, targeting further acquisitions in Europe and expanding into new therapeutic areas.

Laboratoire Polidis has completed its first-ever capital opening. Siparex Entrepreneurs and UI Investissement have joined the company as minority shareholders to support its next growth phase and formalize a new managerial transition.

Nutrisens Group has acquired a majority stake in Prodiet Medical Nutrition, a Brazilian leader in clinical nutrition. The founders of Prodiet, Armando Tortelli and Ana Paula Celes, retain a minority stake and will continue to support the company's growth, while Gabriel Tortelli remains as CEO. This acquisition marks a major step in Nutrisens' international expansion strategy, providing a strong platform to address the Latin American market. The deal is expected to generate significant commercial synergies through cross-selling portfolios and optimizing innovation and sourcing capabilities.

Hemodia, a French healthcare group specializing in the production of sterile medical devices, is reorganizing its capital through a second leveraged buyout (LBO) with the investment fund LBO France. Bpifrance and Multicroissance, existing shareholders since the first LBO, are also reinvesting.